Drug Search Results
More Filters [+]

Sibrotuzumab

Alternative Names: sibrotuzumab
Latest Update: 2024-04-18
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: FAP Binder

Novel Mechanism: Yes

Modality: Antibody

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Boehringer Ingelheim
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Sibrotuzumab

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Colorectal Cancer

Phase 1: Non-Small-Cell Lung Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

NCT02209727

P1

Terminated

Non-Small-Cell Lung Cancer

2002-06-01

NCT02198274

P2

Completed

Colorectal Cancer

2000-10-01

Recent News Events